Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Class I and II Histone Deacetylases (HDACs) are a family of zinc-dependent enzymes that serve as critical "erasers" of epigenetic marks by removing acetyl groups from lysine residues on histones and various non-histone proteins [2, 17]. Class I HDACs (HDAC1, 2, 3, and 8) are primarily nuclear and ubiquitously expressed, playing essential roles in cell proliferation and survival, while Class II HDACs (HDAC4, 5, 6, 7, 9, and 10) exhibit tissue-specific expression and shuttle between the nucleus and cytoplasm to regulate differentiation and signal transduction [1, 3, 4]. By promoting a condensed chromatin state, these enzymes typically function as transcriptional co-repressors, and their dysregulation is a hallmark of many cancers, where they often silence tumor suppressor genes [5, 8, 9]. Beyond oncology, Class I and II HDACs are implicated in neurodegenerative disorders, inflammatory conditions, and cardiovascular diseases [14, 15, 18]. Pharmacological inhibition of these enzymes using HDAC inhibitors (HDACis) leads to the accumulation of acetylated proteins, which can restore normal gene expression, induce cell cycle arrest, and trigger apoptosis in malignant cells [6, 13]. Several HDACis, such as vorinostat and romidepsin, are clinically approved for treating hematological malignancies, although their therapeutic window is often limited by systemic toxicities including myelosuppression and cardiac effects [10, 12, 14].
Class I and II HDAC inhibitors bind to the zinc-containing catalytic domain of the enzymes, blocking their ability to remove acetyl groups from lysine residues on histones and non-histone proteins. This leads to hyperacetylation, which relaxes chromatin structure and allows for the transcriptional reactivation of silenced genes, particularly tumor suppressors like p21. Additionally, inhibition affects the function of non-histone proteins involved in cell signaling, DNA repair, and protein stability, ultimately inducing cell cycle arrest, apoptosis, and senescence in diseased cells.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Class I and II Histone Deacetylases (HDACs) (Class I and II HDACs).